{"status": "OK", "response": {"docs": [{"type_of_material": "Review", "blog": [], "news_desk": "Book Review Desk", "lead_paragraph": "THE BODY By Hanif Kureishi. 149 pp. New York: Scribner. $20.", "headline": {"main": "You've Got to Have Pecs"}, "abstract": "Benjamin Kunkel reviews book The Body by Hanif Kureishi; drawing (M)S", "print_page": "5", "word_count": 1147, "_id": "4fd23c108eb7c8105d7d12f7", "snippet": "THE BODY   By Hanif Kureishi.   149 pp. New York:   Scribner. $20.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/02/29/books/you-ve-got-to-have-pecs.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "creative_works", "value": "BODY, THE (BOOK)"}, {"name": "persons", "value": "KUREISHI, HANIF"}, {"name": "subject", "value": "REVIEWS"}, {"name": "subject", "value": "BOOKS AND LITERATURE"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Benjamin", "lastname": "Kunkel"}], "original": "By Benjamin Kunkel"}, "document_type": "article", "pub_date": "2004-02-29T00:00:00Z", "section_name": "Arts; Books"}, {"type_of_material": "News", "blog": [], "news_desk": "Money and Business/Financial Desk", "lead_paragraph": "AS a founder of four biotechnology companies, Dennis A. Carson can practically write an encyclopedia entry on risk. After all, his first start-up, a gene therapy and vaccine company called Vical, still does not have a product on the market after 16 years and more than $100 million spent. But now Dr. Carson, who is also the director of the cancer center at the University of California at San Diego, is playing it safe, or at least safer. Rather than develop radical new technology or invent new medicines, his latest venture, Salmedix, plans to sell drugs licensed from other companies -- drugs that are already on the market or that have at least gone through some clinical trials.", "headline": {"main": "Is Biotechnology Losing Its Nerve?"}, "abstract": "Many biotechnology companies seem to be taking fewer chances lately, raising concerns that industry may be losing its nerve and will produce fewer innovative drugs; such companies were once known for tackling challenges avoided by big pharmaceutical companies, developing genetically engineered medicines and plunging into experimental research that might never pay off; more and more start-ups now seem focused on scrounging around for existing drugs to license, avoiding toil and risk of trying to find new cause of disease or new compound; some do not even have laboratories; licensing graph; photos (M)", "print_page": "1", "word_count": 2193, "_id": "4fd24f138eb7c8105d7f15c9", "snippet": "AS a founder of four biotechnology companies, Dennis A. Carson can practically write an encyclopedia entry on risk. After all, his first start-up, a gene therapy and vaccine company called Vical, still does not have a product on the market after 16...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/02/29/business/is-biotechnology-losing-its-nerve.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "GENETICS AND HEREDITY"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "RESEARCH"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Andrew", "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2004-02-29T00:00:00Z", "section_name": "Health; Business"}], "meta": {"hits": 2, "offset": 0, "time": 27}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}